What we are seeing in the market.
Operator analysis of health markets in Europe, the US, and MENA: four monthly Vital Signs editions, the PROGNOSIS flagship, perspectives, and the reference work behind them.
Operator analysis of health markets in Europe, the US, and MENA: four monthly Vital Signs editions, the PROGNOSIS flagship, perspectives, and the reference work behind them.
Vital Signs · MedTech
A device can wait about two years between its first approval and its second, and the lead piece sets out what stretched the longest waits. This month's deals show what buyers paid for medtech companies, from $240 million to $2.1 billion, and what Stryker's $400 million in CMR Surgical buys it.
27 October 2026
Perspective · EcosystemHealth innovation hubs turn national health targets in the Middle East and North Africa into solutions for patients and companies that grow the health economy.
News · Venture BuildingHealthSeed and Mangold Consultants are introducing Venitara: AI regulatory tools with senior expert review for medical device, SaMD, and IVD companies.
News · Venture BuildingHealthSeed and MIA Solutions are bringing ZINOS to hospital research units: one clinical trial system, inside the institution, under its own control.